| Project/Area Number |
22K20643
|
|---|
| Research Category |
Grant-in-Aid for Research Activity Start-up
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
0701:Biology at molecular to cellular levels, and related fields
|
|---|
| Research Institution | Shonan Kamakura General Hospital, Medical Corporation Tokushukai (Center for Clinical and |
|---|
Principal Investigator |
Yang Junjie 医療法人徳洲会湘南鎌倉総合病院(臨床研究センター), 湘南先端医学研究所 再生医療開発研究部, 主任研究員 (20962137)
|
|---|
| Project Period (FY) |
2022-08-31 – 2025-03-31
|
| Project Status |
Completed (Fiscal Year 2024)
|
| Budget Amount *help |
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2023: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2022: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | myocardial infarction / exosomes / nanobody / exosome engineering / FoxM1 / targeted delivery / endothelial regeneration / cell cycle / nanobody phage library / ischemic heart disease / phage screening / biopanning / hypoxia / cell engineering / ischemic heart targeted / mesenchymal stem cells / Extracellular Vesicles / Mesenchymal Stem Cells / Myocardial Infarction / Regeneration / Nanobody Phage Library |
|---|
| Outline of Research at the Start |
1) Identify targeting nanobodies by in vivo biopanning of phage display nanobody library in MI mice
2) Engineer MSC-derived EVs with targeting nanobodies
3) Evaluate the therapeutic effects of modified EVs for the treatment of myocardial infarction
|
| Outline of Final Research Achievements |
I have designed a highly diverse and modular phage display library that allows for rapid and efficient replacement of complementarity determining regions. CD29 and CD166 were selected as hypoxia-related proteins in cardiomyocytes.
|
| Academic Significance and Societal Importance of the Research Achievements |
Identifying highly specific and high affinity nanobodies that target ischemic myocardium by biopanning of our novel phage display nanobody library is of vital significance for enhancing EV therapeutic benefits for myocardial infarction.
|
